After Novo Nordisk's acquisition of Corvidia, Ram Aiyar takes the helm at Korro Bio; Silverback gets a new CFO to go along with its IPO
→ Co-founded by Nessan Bermingham and banking $91.5 million in Series A funding in September, RNA editing startup Korro Bio has tapped Ram Aiyar as their first CEO. Aiyar, who began as a research scientist in the immunology group at Janssen in the late 2000s, co-founded Corvidia Therapeutics in 2016 and was also their CFO and CBO along the way. Back in June, Aiyar helped steer the sale of Corvidia to Novo Nordisk for $2.1 billion, including $725 million upfront. With the deal, Novo Nordisk inserted Corvidia’s IL-6 inhibitor ziltivekimab into their pipeline.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.